领航医药生物科技(00399.HK) 发盈警,与上年度净利润9,870万元相比,预计3月止财政年度亏损介乎5.5亿至6亿元。预期亏损主要源于与口服胰岛素产品研发进程相关的无形资产减值损失介乎2.5亿至3.5亿元;及可换股债券产生的有效利息支出约2.59亿元。(de/d)(港股报价延迟最少十五分钟。)过往派息公布日期派息事项派息内容2024/11/29中期业绩无派息2024/06/28末期业绩无派息...
Source Link领航医药生物科技(00399.HK) 发盈警,与上年度净利润9,870万元相比,预计3月止财政年度亏损介乎5.5亿至6亿元。预期亏损主要源于与口服胰岛素产品研发进程相关的无形资产减值损失介乎2.5亿至3.5亿元;及可换股债券产生的有效利息支出约2.59亿元。(de/d)(港股报价延迟最少十五分钟。)过往派息公布日期派息事项派息内容2024/11/29中期业绩无派息2024/06/28末期业绩无派息...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.